新华社日内瓦12月12日电（记者王露）世界卫生组织11日发布声明说，该组织全球疫苗安全咨询委 员会的最新分析报告指出，现有证据表明疫苗与孤独症之间不存在因果关系。 根据审查结果，委员会重申其在2002年、2004年和2012年的既有结论：包括含硫柳汞疫苗和含铝疫 苗在内的疫苗均不会导致孤独症。 全球疫苗安全咨询委员会成立于1999年，就全球疫苗安全相关的重点事项向世卫组织提供独立、权 威的科学建议。 声明说，这份报告关注含硫柳汞疫苗以及普通疫苗与孤独症之间的关联。基于2010年1月至2025年8 月期间发表的31项研究的证据，报告有力支持了儿童时期和孕期接种疫苗的安全性，证实疫苗与孤独症 之间不存在因果关系。 此外，委员会根据1999年至2023年3月期间的多项研究，以及一项分析了丹麦全国1997年至2018年 出生儿童登记数据的大型队列研究，评估了含铝佐剂疫苗相关的潜在健康风险。证据表明，某些含有微 量铝的疫苗与孤独症之间没有关联，该结论支持继续使用含铝佐剂疫苗。 声明还说，全球儿童免疫接种是改善健康、生活和社会福祉的重大成就之一。过去50年，儿童免疫 接种至少挽救了1.54亿人的生命。 ...

在一份官方备忘录提及10例儿童接种后死亡案例后，FDA正调查"多个年龄组"的死亡事件；此前研究已 表明严重不良反应极为罕见。 责任编辑：张俊 SF065 在一份官方备忘录提及10例儿童接种后死亡案例后，FDA正调查"多个年龄组"的死亡事件；此前研究已 表明严重不良反应极为罕见。 责任编辑：张俊 SF065 ...

多地接种量走高 在郑州、厦门、广州等地社区卫生服务中心，国产九价接种量上升的趋势在现场就能直观感受到：接种区前等候的人比以往更多，咨询台 不时有人询问接种流程等问题。与此前九价HPV疫苗"难约"的印象不同，如今在不少接种点里，国产九价的热度正以更直接、可感的方式 显现出来。 国产九价的增长趋势尤为明显。郑州博学路社区卫生服务中心工作人员介绍，国产九价上线后，预约量和接种量显著提升，占日常九价 HPV疫苗接种总量的六成以上。在厦门，位于海沧区新阳街道社区卫生服务中心里，该接种点每周完成国产九价的接种约两百剂次，约占 所有接种HPV疫苗的比例为60%左右。在广州，一家社区卫生服务中心后台数据显示，一个多月内已有八百多名居民预约国产九价，实际 到接种环节中"已有过半选择国产"。 国产九价HPV疫苗自首针开打以来，随着在多省份陆续进入常规接种渠道，部分社区卫生服务中心普遍出现咨询量和接种量同步增长的态 势。来自多地基层接种点的反馈显示，随着疫苗供应愈加稳定、可及性不断提升，国产九价HPV疫苗在部分地区的接种占比持续走高，正 成为越来越多女性在九价HPV疫苗接种中的优先选择。 厦门市妇幼保健院妇女保健科主任李清认为，国 ...

Core Viewpoint - The Trump administration's health officials plan to present claims linking COVID-19 vaccines to 25 child deaths to a key vaccine advisory committee, impacting biotech stocks negatively [1] Group 1: Impact on Biotech Stocks - Following the news, U.S. biotech stocks experienced significant declines, with BioNTech down 7.26%, Pfizer down 3.98%, Moderna down 7.40%, and Novavax down 3.62% [1] - Citigroup highlighted the volatility risk for biotech companies due to the news, emphasizing the robust research supporting COVID-19 vaccines and billions of doses administered [1] Group 2: Company Ratings by Citigroup - **BioNTech**: Rated "Buy" with a target price of $140, but considered "high risk" due to typical volatility in biotech stocks and uncertainties in clinical trials [3] - **Moderna**: Rated "Neutral" with a target price of $30, also deemed "high risk" with potential down risks related to market stability and product effectiveness [4] - **Novavax**: Rated "Sell" with a target price of $6, facing risks but with potential upside if the COVID-19 vaccine market recovers unexpectedly [5] - **Pfizer**: Target price set at $26, with both upside and downside risks related to new drug sales and competitive pressures [6]

Group 1 - Pfizer (PFE.US) and Moderna (MRNA.US) stocks fell sharply following reports that Trump administration health officials plan to present claims linking COVID-19 vaccines to 25 child deaths to a key vaccine advisory committee next week [1][2] - The Advisory Committee on Immunization Practices (ACIP) is responsible for reviewing vaccination data and making recommendations that significantly influence vaccine policy [1][2] - Following the news, Pfizer's stock dropped by 3.98%, Moderna's stock fell by 7.4%, and Novavax (NVAX.US) also saw a decline of 3.62% [1] Group 2 - The U.S. Department of Health and Human Services (HHS) stated that the FDA and CDC regularly analyze vaccine safety data and share results through established ACIP processes, emphasizing that any unverified claims should be considered speculation [1][2] - Moderna highlighted that the safety of its vaccine is being closely monitored by the company, FDA, and regulatory agencies in over 90 countries, with no new safety concerns reported in systems monitoring across various regions [2] - Research indicates that mRNA vaccines produced by Pfizer and Moderna are safe and effective, with severe adverse reactions being extremely rare, although there is a slight increase in myocarditis risk among young males [2][3] Group 3 - FDA Director Marty Makary acknowledged that there have been self-reported cases of child deaths following COVID-19 vaccination, but did not provide specific data, stating that a report will be released in the coming weeks [3] - The claims made by the Trump administration appear to be based on data from the Vaccine Adverse Event Reporting System (VAERS), which collects self-reported data that requires thorough investigation to determine causality [2]